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ABSTRACT 
 
This pilot study explores relationships between clinical and socio-demographic 
characteristics and abnormal comprehensive stool analysis (CSA) results of patients at the 
Integrative Medicine Clinic at the University of Kansas Medical Center, to evaluate 
comprehensive stool analysis as a potential tool to stratify patients by risk of developing 
gastrointestinal disease as a first step to defining personalized risk reduction strategies. The 
primary hypothesis was that Integrative Medicine Clinic patients with lower socioeconomic 
status, chronic disease, poor nutritional status, and/or general health risks would be more likely 
than other patients to have abnormal bacterial counts and abnormally low levels of short-chain 
fatty acids.  Data were abstracted from paper charts in the Integrative Medicine Clinic, 
representing current adult patients in the clinic with comprehensive stool analysis reports in their 
files (N=295).  Analysis of the available data revealed that not all relevant data (race/ethnicity, 
occupation, household income) were recorded for all patients, making correlations between the 
outcomes of interest and certain socio-demographic variables impossible.  However, 
multivariable relative risk regression revealed that stomach pain, fecal pH, and methylation 
insufficiency were significant predictors of abnormally low levels of total short chain fatty acids, 
while abnormal lactoferrin levels, and detoxification genome markers NAT2*K268R and 
NAT2*I114T were significant predictors of abnormally low levels of the beneficial Bifidobacter 
bacterial species. Future work should establish CSA baseline results in a larger, more 
generalizable population and follow a cohort prospectively to establish the relationship between 
abnormal CSA and disease risk.  
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INTRODUCTION 
According to the Surveillance, Epidemiology, and End Results (SEER) Program and the 
National Center for Health Statistics (http://seer.cancer.gov), colorectal cancer (CRC) is the third 
most common cancer diagnosed regardless of gender, and is the third leading cause of cancer-
related death.  It is estimated that approximately $8.4 billion is spent yearly on colorectal cancer 
treatment in the United States alone (http://progressreport.cancer.gov).  Preventive measures 
involving education, routine colonoscopy, fecal occult blood testing, and behavioral changes to 
improve colon health have become imperative in reducing the incidence and treatment costs of 
CRC.  As a result, comprehensive stool analysis (CSA) has become a useful tool in evaluating 
the general health and integrity of the digestive tract, examining both structural and functional 
parameters which may further play a role in prevention of gastrointestinal symptoms and CRC 
(Rafter, 2002; Rowland, 2009). 
 Increased research interest has recently been focused on the impact of gastrointestinal 
bacteria on health (Brady et al., 2000; Pregliasco et al., 2008). The human microbiota comprises 
approximately 1014 bacterial cells, with gastrointestinal tract colonization representing around 
75% of the total microbes (Naito et al., 2010). The majority of gastrointestinal bacteria fall into 6 
major species: Bacteriodes, Bifidobacterium, Eubacterium, Clostridium, Lactobacillus, and 
Fusobacterium (Wallace et al., 2011). The bacterial numbers steadily increase from duodenum 
(102 bacteria/gram) to colon (~1012 bacteria/gram). Bacilli are enriched in the small intestine 
while Bacteriodes are enriched in the colon (Frank and Pace, 2001). The mucus layer generates 
additional heterogeneity by separating the bacteria confined to the intestinal lumen from those 
able to invade below the mucus and attach to the epithelium (Swidsinski et al., 2005). 
Microbiotic digestion of dietary fiber and modulation of dietary lipids also contribute to bacterial 
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diversity (Vella and Farrugia, 1998; Bäckhed et al., 2004; Turnbaugh et al., 2006; McFarland, 
2008).  
The gut is populated by bacteria shortly after birth, and the bacterial composition of the 
gut flora is established by around two years of age (Mackie et al., 1999; Fanaro et al., 2003). The 
microbiota composition of each individual is relatively constant over time and is influenced by 
both individual characteristics and by exposures early in life  (Eckburg et al., 2005; Ley et al., 
2006; Kelsall, 2008).   Studies now suggest that health promoting beneficial digestive tract 
microflora can influence various GI processes and may also relate to the production of adequate 
amounts of short-chain fatty acids, and thus promote nutrient absorption through production of 
digestive enzymes, vitamin synthesis, and immune function, while also inhibiting colonization 
by pathogens (Weaver et al., 1988; Delzenne et al., 2003; Boutron-Ruault et al., 2005; Lim et al., 
2005; Hamer et al., 2008; Liong, 2008; Corfe et al., 2009; Worthley et al., 2009; Garrett et al., 
2010).   
Few human trials have been conducted to further explore the role of the short-chain fatty 
acids (SCFA) themselves, or the profile of beneficial bacteria required to produce them, in 
helping to prevent colorectal cancer or other gastrointestinal disorders (Delzenne et al., 2003; 
Geier et al., 2006; Rafter et al., 2007; Fotiadis et al., 2008). Research has demonstrated, however, 
that one of the short-chain fatty acids (butyrate) is a preferred energy source of colonocytes 
(Greer and O'Keefe, 2011). Other studies have demonstrated that certain bacterial species have 
been linked to increased risk of gastrointestinal diseases, including colorectal cancer, through 
production of toxic metabolites or promotion of chronic inflammation that patients with CRC 
have modified bacterial profiles (Rowland, 2009; Castellarin et al., 2011; Kostic et al., 2011; 
Marchesi et al., 2011; Sobhani et al., 2011; Wang et al., 2011). Bifidobacterium and 
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Lactobacillus species have been shown to produce low levels of carcinogen-forming metabolites 
and to bind to certain carcinogens and physically prevent their absorption (Liong, 2008), and 
have consequently been of particular interest for their potential health benefits.  Therefore, 
bacteria and the metabolites these organisms produce in the gut may be an important modifiable 
factor related to CRC risk. In addition, while bacterial profiles appear stable, relative distribution 
of bacterial types can be influenced by various environmental exposures including diet, 
medication, and smoking behavior  (Parry et al., 2005; O'Keefe, 2008; Jernberg et al., 2010). 
Many of these biological and environmental factors, if characterized and understood through 
methods including comprehensive stool analysis, could potentially be clinically modified or 
considered in personalized screening approaches and risk reduction strategies. 
As a first step in the development of potential personalized risk reduction strategies for 
general GI health, the aim of the present study was to examine relationships between patient 
clinical and socio-demographic characteristics and CSA findings in a group of patients evaluated 
in the Integrative Medicine Clinic at the University of Kansas Medical Center, with the 
hypothesis that Integrative Medicine Clinic patients with lower socioeconomic status, chronic 
disease, poor nutritional status, and/or general health risks would be more likely than other 
patients to have abnormal bacterial counts and abnormally low levels of short-chain fatty acids. 
METHODS 
 This exploratory pilot study included a convenience sample of adult (age 18 or older at 
the time of first clinic visit) Integrative Medicine patients with charts currently on file in the 
Integrative Medicine Clinic at the University of Kansas Medical Center (KUMC). All charts 
were reviewed for the presence of a comprehensive stool analysis report, and those lacking such 
a report were excluded.  A total of 295 patient charts were included in this retrospective cross-
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sectional study. Data from paper based medical charts were abstracted for each patient by a 
research assistant, who recorded demographic and general health information from each patient’s 
initial clinic intake form, clinical data from each patient’s initial CSA laboratory report, personal 
and family history of GI symptoms/disease, physiological profile, and genetic detoxification 
profile.  Demographic data included patients’ age, gender, race/ethnicity, marital status, and level 
of education. General health information abstracted from patient charts included height and 
weight, smoking status and alcohol use, symptoms of headache, allergies, sinus issues, low back 
pain, and arthritis. The physiological profile consisted of a food allergy panel (KU PIM IgG 
Food Panel II, IBT Laboratories, Lenexa, KS), a neurotransmitter metabolite panel (epinephrine, 
norepinephrine, and histamine) (NeuroScreen Expanded, NeuroScience, Inc., Osceola, WI), plus 
additional general chemistry (copper, zinc), cardiac (homocysteine), and vitamin and mineral 
panel (vitamins A, B complex, D, E) markers.  The genetic detoxification profile (Genovations 
Detoxigenomic Profile, Genova Diagnostics, Asheville, NC) characterizes 22 single nucleotide 
polymorphisms (SNPs) associated with metabolism of toxic compounds, including enzymes 
involved in hydroxylation (cytochrome P450 enzyme family), methylation (catechol-O-methyl 
transferase) and acetylation (N-acetyl transferase). Data from the abstraction sheets were 
subsequently entered into a Microsoft Excel spreadsheet for data cleaning, and then converted to 
a SPSS data file for analysis. This study was approved under full committee review by the 
Institutional Review Board of the University of Kansas Medical Center. 
CSA reports were received from two different laboratories (Doctor’s Data and Metametrix), 
depending on when the patient was seen at the Integrative Medicine clinic. While both labs 
reported the same basic information, some of the variables did not have the same units. 
Specifically, the variables with differing values include: Elastase 1 - (µg/ml – Doctor’s Data, 
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µg/g – Metametrix), N-Butyrate – (mg/ml - Doctor’s Data, mM/g - Metametrix), Lactobacillus 
and Bifidobacter – (0-4+ scale – Doctor’s Data,  millions of colony forming units/gram of stool – 
Metametrix), and total short chain fatty acids (TSFCA) – (mg/ml – Doctor’s Data, mM/g – 
Metametrix).  Elastase 1 and N-Butyrate values were in units that were not able to be converted 
between the two labs, and so were excluded from additional analyses.  Lactobacillus and 
Bifidobacter counts were of particular interest as outcome variables, so the Metametrix data were 
converted to a 0-4 scale based on quintile values obtained from the laboratory.  In addition, a 
new binary outcome variable indicating clinically low values (<1), were created for both 
Lactobacillus and Bifidobacter to reflect abnormal levels of each of these beneficial bacterial 
species. For TSCFA, the third outcome variable, abnormal values were determined based on the 
reference ranges for each lab, and a new binary variable was created to indicate those patients 
with abnormally low TSCFA levels.   
 Outcome variables (abnormal TSCFA, abnormal Lactobacillus and abnormal 
Bifidobacter) were coded as binary conditions, where abnormal = 1 and normal = 0, and because 
the frequency of each of these outcomes was found to exceed 10%, relationships between 
predictor and outcome variables were evaluated using relative risk regression with an underlying 
log binomial distribution. Bivariable relative risk regression analysis between each predictor 
variable and the outcome variables of interest were performed to identify predictors with p < 
0.20 for inclusion in multiple logistic regression analysis. Multiple relative risk regression 
models were constructed to explore predictive factors on abnormal CSA results.  Relative risk 
regression models were evaluated using the Bayesian Information Criterion (BIC) statistic, 
which provides an asymptotic approximation to the Bayesian posterior probability of a particular 
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candidate model (Schwarz, 1978). A regression model with the lowest BIC is considered the best 
fit for the data. Statistical analysis was conducted in SPSS v. 18 and SAS v. 9.2. 
RESULTS 
Frequencies of categorical predictor variables and mean and standard error of continuous 
predictor variables used in regression modeling are presented in Table 1.  Predictor variables 
which had more than 100 missing values or fewer than 25 individuals in a particular category 
were excluded from the primary analysis (indicated by * in Table 1).  Because only a subset of 
the sample (N=95) had data from the detoxification genome profile, these data were analyzed 
separately as a subgroup analysis.  Genetic detoxification profile markers, which had fewer than 
10 in a particular category were excluded from this analysis (indicated by * in Table 1). Using 
the Kolmogorov-Smirnov normality test, all of the continuous predictor variables were found to 
not be normally distributed, with the exception of age and pH.  Because of this, and because 
there are clinically significant cut-off values for abnormal levels of the physiological and CSA 
continuous variables, these were converted to binary normal/abnormal variables for further 
analysis.  In addition, pilot research in the Integrative Medicine Clinic has indicated that 
abnormal levels of histamine, homocysteine, and norepinephrine/epinephrine ratio are associated 
with methylation insufficiency, so a composite variable (methylation status) was created to 
indicate when 2 of these 3 variables were in the abnormal range.  The biochemical process of 
methylation is important for production of phospholipids, epigenetic control of gene expression, 
and synthesis of proteins and various neurotransmitters, and so may have an effect on general 
health status (Bottiglieri, 2002). 
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Table 1. Predictor variables used in regression modeling. 
Demographic N Total N 
Gastrointestinal 
Symptoms N (Yes) N (No) 
Gender Male =91 295 Constipation 131 163 
Race/ 
Ethnicity* White =84 89 Diarrhea 101 193 
Marital Status Married = 210 290 Heartburn 64 230 
Education 
College Graduate 
=126 286 Stomach Pain 107 186 
 Mean (SE) Total N Nausea 53 240 
Age 50.51 (0.867) 295 Vomiting 27 266 
   Bloating 115 179 
General Health Mean (SE) Total N 
Comprehensive 
Stool Analysis N (Yes) N (No) 
Height* 66.91 (0.331) 160 Yeast 129 166 
Weight 158.68 (2.378) 275 Parasites 39 255 
General Health N (Yes) N (No) Dysbiotic Flora 84 207 
Smoker* 13 280 Fecal Sig A 215 77 
Alcohol 221 72 WBC* 2 291 
Arthritis 87 207 Mucus* 3 290 
Low Back Pain 139 155 Occult Blood* 11 283 
Allergic 
Rhinitis* 18 276 
Comprehensive 
Stool Analysis Mean (SE) N 
Sinus Issues 105 189 pH 6.52 (0.327) 294 
Headache 123 171 Lactoferrin 3.26 (0.934) 293 
Personal History 
of GI Disease N (Yes) N (No) 
Physiological 
Profile Mean (SE) Total N 
PH IBS 107 187 Copper/Zinc Ratio 
1.452 
(0.365) 277 
 
PH Chrohns* 6 288 25-OH Vitamin D 
3838.951 
(1.325) 270 
PH Ulcerative 
Colitis* 4 290 Vitamin B-6 
37.668 
(2.284) 264 
PH Peptic 
Ulcers* 7 287 Homocysteine 
9.361 
(0.274) 257 
PH GERD 41 253 Urinary Histamine 
20.722 
(0.504) 248 
PH Celiac* 11 283 
Urinary 
Norepinephrine/ 
Epinephrine Ratio 
5.649 
(0.223) 253 
PH Colon 
Cancer* 6 288 
Physiological 
Profile N (Yes) N (No) 
   Food Sensitivity 62 186 
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Family History of 
GI Disease N (Yes) N (No) 
Genetic 
Detoxification 
Profile N (Yes) N (No) 
FH IBS* 22 272 CYP1A 20 75 
FH Chrohns* 7 287 CYP1B 83 12 
FH Ulcerative 
Colitis* 3 291 NAT2*I114T 33 61 
FH Peptic 
Ulcers* 4 290 NAT2*R197Q 52 42 
FH Gerd* 4 290 NAT2*G286E* 3 91 
FH Celiac* 11 283 NAT2*R64Q* 0 94 
FH Colon 
Cancer* 18 276 NAT2*K268R 57 37 
   COMT*V158M 77 18 
Supplements N (Yes) N (No) Supplements N (Yes) N (No) 
Probiotics 215 73 Vitamin D 175 144 
Zinc 127 162 Vitamin B6 125 164 
 
For abnormal TSCFA status, 19 variables were found to be associated with a p < 0.2 
(Table 2): male gender, age, marital status, having greater than a high school education, weight, 
sinus issues, alcohol consumption, taking zinc supplements, personal history of irritable bowel 
syndrome (PH_IBS) or gastroesophageal reflux (PH_GERD), symptoms of diarrhea, heartburn, 
stomach pain, or bloating, presence of yeast, sigA, or dysbiotic flora in stool, stool pH, 
methylation status, and abnormal copper/zinc ratio. Of these 19 variables associated with 
abnormally low TSCFA levels, graduate education, sinus issues, personal history of GERD, 
diarrhea, heartburn, stomach pain, fecal dysbiotic flora, fecal pH, and abnormal copper/zinc ratio 
had p-values <0.05. None of the other physiological variables nor the genetic detoxification 
profile variables were associated with abnormally low TSCFA levels. 
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Table 2. Bivariate relative risk regression for abnormal TSCFA status, predictors with p < 0.2. 
Parameter Relative Risk 95% CI P (Parameter Estimate) 
Gender (Male) 0.66 0.41-1.07 0.094 
Age 1.01 1.00-1.02 0.135 
Married (relative to single) 1.28 0.70-2.34 0.420 
Widowed/Divorced (relative to single) 1.79 0.85-3.76 0.127 
College Education (relative to HS only) 1.24 0.66-2.35 0.502 
Graduate Education (relative to HS 
only) 
1.53 0.82-2.86 0.178 
Weight 1.00 0.99-1.00 0.143 
Sinus Issues 1.61 1.09-2.38 0.017 
Alcohol Consumption 0.71 0.47-1.07 0.102 
Supplement: Zinc 1.32 0.89-1.97 0.168 
Personal History of Irritable Bowel 
Syndrome 
1.41 0.95-2.09 0.089 
Personal History of Gastroesophageal 
Reflux Disease 
1.68 1.07-2.62 0.023 
Diarrhea 1.63 1.11-2.41 0.014 
Heartburn 1.63 1.08-2.45 0.019 
Stomach Pain 2.09 1.41-3.10 0.0003 
Bloating 1.30 .088-1.93 0.192 
Fecal Yeast 0.74 0.49-1.12 0.160 
Fecal Dysbiotic Flora 0.46 0.25-0.82 0.009 
Fecal Sig A 1.37 0.83-2.27 0.215 
Fecal pH 2.82 1.98-4.01 <0.0001 
Methylation Status 0.45 0.23-0.89 0.023 
Copper/Zinc Ratio Abnormal 1.60 1.00-2.57 0.050 
 
The first model examining predictors of abnormal total short chain fatty acid status excluded the 
physiological and detox genome markers, and failed to converge (Table 3). Given this failure of 
the first model using backwards stepwise regression, a forward selection model was developed 
using those predictors with the highest relative risk whose 95% CI did not include 1. This 
restricted model included the variables stomach pain – RR: 1.84 (1.22-2.76, p = 0.004) and fecal 
pH – RR: 2.36 (1.73-3.21, p <0.0001), both of which were significant predictors of abnormal 
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TSCFA status. Forward regression from this restricted model including additional variables with 
p<0.2 produced only one model with an additional significant predictor, methylation status. 
 
Table 3. Multiple Logistic Regression models for TSCFA status.  
Variables in model BIC Relative Risk 95% CI p 
Gender (Male) 
Age 
Marital Status  
  Single 
  Currently Married 
  Previously Married 
Education 
  High School 
  College Graduate 
  Postgraduate  
Weight 
Sinus Issues 
Alcohol Consumption 
Supplements: Zinc 
PH_IBS 
PH_GERD 
Diarrhea 
Heartburn 
Stomach Pain 
Bloating 
Fecal Yeast 
Fecal Sig A 
Dysbiotic Flora 
Fecal pH 
-- *model failed to converge -- -- 
Stomach Pain 
pH 
287.615 
(N=271) 
1.84 
2.36 
1.22-2.76 
1.73-3.21 
0.004 
<0.0001 
Stomach Pain 
pH 
Methylation Status 
265.708 
(N=237) 
2.00 
2.10 
0.34 
1.30-3.10 
1.50-2.95 
0.17-0.69 
0.002 
<0.0001 
0.003 
*Forward relative risk regression did not produce models with additional significant variables. 
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Table 4. Bivariate Relative Risk Regression Analysis for Lactobacillus status: Predictors (p < 
0.2). 
Parameter Relative Risk 95% CI P (Parameter Estimate) 
Diarrhea 0.75 0.52-1.09 0.1289 
Constipation 1.27 0.92-1.75 0.1435 
Personal History of GERD 0.62 0.34-1.13 0.1151 
Weight 1.00 1.00-1.01 0.1214 
Vitamin B6 Abnormal 0.74 0.49-1.11 0.1453 
Histamine Abnormal 0.79 0.56-1.11 0.1754 
CYP1A Polymorphism 0.50 0.20-1.25 0.1395 
 
 Bivarable relative risk regression of predictors for Lactobacillus status revealed 7 
variables with a p<0.2: diarrhea, constipation, PH_GERD, weight, abnormal B6 and abnormal 
histamine levels, and CYP1A polymorphism (Table 4).  These predictors were used in further 
relative risk regression modeling. Because fewer subjects had results for the physiological and 
detox genome profile markers, the first model included only the symptom, patient history, and 
weight variables (Table 5).  This full model produced no significant predictors of risk of 
abnormal levels of Lactobacillus in CSA. Permutations of models including only the GI 
symptoms as parameters also did not produce any significant predictors. When abnormal 
histamine and abnormal B6 are added to the full model, one significant predictor is found, 
weight (p = 0.03) However, with a relative risk of 1.00 (95% CI: 1.00-1.01), the actual clinical 
significance of this finding is questionable. The addition of the detoxification genome marker 
CYPIA to the model also did not produce additional significant predictors. In the bivariate 
logistic regression analysis of associations with abnormal Lactobacillus status, all of the 95% CI 
for the odds ratios included 1, indicating that there was likely no significant difference in 
Lactobacillus status by these predictor variables.  Multiple relative risk regression analysis has 
born this out, with none of the models predicting Lactobacillus status well (c: 0.576-0.751). 
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Table 5. Multiple relative risk regression modeling for Lactobacillus status 
Variables in model BIC Significant 
variables  
p 
Diarrhea 
Constipation 
PH_GERD 
Weight 
368.120 
(N=274) 
None – 
Diarrhea 
Constipation 
PH_GERD 
390.343  
(N=294) 
None – 
Constipation 
PH_GERD 
 
Diarrhea 
Constipation 
 
Diarrhea 
PH_GERD 
386.789 
(N=294) 
 
688.316 
(N=294) 
 
387.126 
(N=294) 
None 
 
– 
Diarrhea 
Constipation 
PH_GERD 
Weight 
B6 Abnormal 
Histamine Abnormal 
297.748 
(N=213) 
ns 
ns 
ns 
1.00 (1.00-1.01) 
ns 
ns 
 
 
 
0.030 
Diarrhea 
Constipation 
PH_GERD 
B6 Abnormal 
Histamine Abnormal 
310.576 
(N=226) 
None – 
Diarrhea 
Constipation 
PH_IBS 
PH_GERD 
Weight 
B6 Abnormal 
Histamine Abnormal 
CYP1A 
119.988 
(N=77) 
None – 
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Variables in model BIC Significant 
variables  
p 
Diarrhea 
Constipation 
PH_IBS 
PH_GERD 
B6 Abnormal 
Histamine Abnormal 
CYP1A 
119.095 
(N=81) 
None – 
 
For Bifidobacter status, 15 variables had a p <0.2: College Education, Sig A, Dysbiotic 
Flora, Lactoferrin Abnormal, Supplements: B6, Diarrhea, Constipation, Food Sensitivity, Low 
Back Pain, Alcohol, B6 Abnormal, Methylation Status Abnormal, NAT2*K268R Polymorphism, 
NAT2*I114T Polymorphism, and CYP1A Polymorphism (Table 6).   
 
Table 6. Bivariate Relative Risk Regression for Bifidobacter status 
Parameter Relative Risk 95% CI P (Parameter Estimate) 
College Education 1.31 0.91-1.89 0.1484 
Sig A 0.84 0.67-1.05 0.1295 
Dysbiotic Flora 1.27 1.02-1.57 0.0291 
Lactoferrin Abnormal 1.35 1.09-1.67 0.0059 
Supplements: Vitamin B6 1.15 0.93-1.43 0.1962 
Diarrhea 1.19 0.96-1.48 0.1050 
Constipation 0.84 0.67-1.05 0.1317 
Food Sensitivity 1.20 0.94-1.53 0.1410 
Low Back Pain 1.24 1.00-1.53 0.0540 
Alcohol 1.20 0.91-1.59 0.1893 
Vitamin B6 Abnormal 0.79 0.60-1.05 0.1036 
Homocysteine Abnormal 0.85 0.68-1.08 0.1788 
NAT2*K268R 
Polymorphism 
1.63 0.96-2.75 0.0714 
NAT2*I114T Polymorphism 1.73 0.98-3.06 0.0591 
CYP1A Polymorphism 1.81 1.21-2.71 0.0040 
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Table 7. Multiple relative risk regression modeling for Bifidobacter status 
Variables in model BIC Relative Risk (95% CI) p 
Education 
Dysbiotic Flora 
SigA 
Lactoferrin Abnormal 
Supplements: B6 
Diarrhea 
Constipation 
Food Sensitivity 
Low Back Pain 
Alcohol 
– *model failed to converge – 
Lactoferrin Abnormal 
Dysbiotic Flora 
389.847 
(N=278) 
1.24 (1.00-1.53) 
1.35 (1.09-1.66) 
0.0486 
0.0051 
Lactoferrin Abnormal 
Dysbiotic Flora 
Food Sensitivity 
333.974 
(N=235) 
1.34 (1.06-1.66) 
ns 
1.27 (1.01-1.58) 
0.0127 
 
0.0383 
Lactoferrin Abnormal 
Food Sensitivity 
338.750 
(N = 239) 
1.34 (1.06-1.67) 
ns 
0.0143 
Lactoferrin Abnormal 
Dysbiotic Flora 
NAT2*K268R  
NAT2*I114T  
CYP1A 
– *model failed to converge – 
Lactoferrin Abnormal 
NAT2*K268R  
NAT2*I114T  
CYP1A  
132.137 
(N=90) 
1.74 (1.09-2.77) 
ns 
ns 
ns 
0.0196 
Lactoferrin Abnormal 
CYP1A 
130.797 
(N=91) 
1.53 (0.97-2.43) 
1.48 (0.97-2.25) 
0.0699 
0.0704 
Lactoferrin Abnormal 
NAT2*K268R  
126.936 
(N=90) 
1.78 (1.15-2.75) 
1.65 (1.00-2.72) 
0.0092 
0.0492 
Lactoferrin Abnormal 
NAT2*I114T** 
125.773 
(N=90) 
1.83 (1.19-2.80) 
1.80 (1.05-3.09) 
0.0063 
0.0336 
**Forward regression from this model did not produce any additional significant predictors. 
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The first model examining predictors of abnormal Bifidobacter status excluded the 
physiological and detox genome markers, and failed to converge due to the relative Hessian 
convergence criterion being greater than the limit (0.0058 > 0.0001) (Table 7). Given this failure 
of the first model using backwards stepwise regression, a forward selection model was developed 
using those predictors with the highest relative risk whose 95% CI did not include 1.  This 
revised model included the variables dysbiotic flora and abnormal lactoferrin level, both of 
which were significant predictors of abnormal Bifidobacter status.  Forward regression from this 
restricted model identified food sensitivity –RR: 1.27 (1.01-1.58) as an additional significant 
predictor of abnormal Bifidobacter levels. Inclusion of food sensitivity in the model resulted in 
dysbiotic flora no longer being a significant predictor. However, a restricted model including 
abnormal lactoferrin and food sensitivity showed that food sensitivity was not a significant 
predictor of the outcome, after accounting for abnormal lactoferrin.  Inclusion of the 
physiological markers to this model, individually and in combination, did not result in additional 
significant predictors.  Adding the three detoxification genome markers (CYP1A, 
NAT2*K268R, NAT2*I114T) to the model including dysbiotic flora and abnormal lactoferrin 
levels again resulted in a model that failed converge due to the relative Hessian convergence 
criterion being greater than the limit of 0.0001.  Excluding dysbiotic flora from this model 
including the genome markers showed only abnormal lactoferrin level to be a significant 
predictor of abnormal Bifidobacter status.  Examining the detoxification genome markers 
individually in models including abnormal lactoferrin showed that all three are significant 
predictors of abnormal Bifidobacter status after controlling for abnormal lactoferrin, though the 
95% CI for CYP1A includes 1, and the models looking at the contribution of NAT2*K268R and 
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NAT2*I114T both had lower BIC values (suggesting that they are better models for predicting 
abnormal Bifidobacter status). 
DISCUSSION 
This exploratory pilot study does not support the primary hypothesis that those with 
lower socioeconomic status (SES) would be more likely to have abnormal levels of total short 
chain fatty acids or beneficial gut bacteria.  Only one variable related to socioeconomic status 
was available from the retrospective chart review, level of education.  There was no information 
on income or occupation in the records, and the other proxy for SES (race/ethnicity) was only 
recorded for 89 patients, 84 of whom were White.  
There is some suggestion from this study that chronic gastrointestinal diseases do impact 
TSCFA levels, as personal history of gastroesophageal reflux and irritable bowel syndrome 
showed a trend (p < 0.2) with abnormally low total short chain fatty acid levels. However, in the 
multivariable regression models, neither condition was significant in predicting abnormal 
TSCFA levels. Instead, abnormal methylation status showed a protective effect on abnormal 
TSCFA – RR: 0.34 (0.17-0.69, p = 0.003), after accounting for the effects of stomach pain and 
fecal pH. None of the components of the composite variable methylation insufficiency (i.e., 
abnormal histamine, abnormal homocysteine, and abnormal norepinephrine/epinephrine ratio) 
were associated with low TSCFA. Future work, using a larger sample size and healthy 
volunteers, should explore these components and examine if any particular one contributes more 
to abnormal levels of total short chain fatty acids. 
None of the multivariable relative risk regression models were adequate in predicting 
abnormal Lactobacillus status.  For Bifidobacter, abnormal lactoferrin levels, as well as several 
of the detoxification genome markers (CYP1A, NAT2 K268R, NAT2 I114T), showed a 
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significant increase in the risk for abnormal levels. Lactoferrin in stool is a marker of 
inflammation, and in a clinical context, can be used to distinguish patients with active 
inflammatory bowel disease from those with irritable bowel syndrome (Dai et al., 2007). The 
detoxification genes, CYP1A and NAT2, produce enzymes which are active in the breakdown of 
heterocyclic amines, potentially carcinogenic compounds produced from cooking meat (Huycke 
and Gaskins, 2004). CYP1A codes for a protein that belongs to the large cytochrome p450 
enzyme family, which metabolizes steroid hormones and other fat-soluble molecules and 
oxidizes potentially toxic compounds (Liong, 2008). NAT2, a gene expressed primarily in the 
liver and GI tract, codes for n-acetyltransferase, an enzyme active in acetylation metabolic 
pathways. The K268R polymorphism signifies a fast metabolizer genotype, which may lead to 
mistakes in the acetylation process and failure to fully neutralize toxic compounds. The I114T 
polymorphism, in contrast, confers a slow metabolizer genotype, which could lead to the build 
up of toxic substances in the gut. Both NAT2 genotypes have been associated with increased risk 
of CRC, and the results of the present study suggest a possible interaction between host genotype 
and the intestinal microbiome (Frank et al., 2011). In addition, Bifidobacter species have been 
shown to bind to certain carcinogenic byproducts of heterocyclic amine metabolism, revealing a 
potential mechanism for such an interaction (Zhang and Ohta, 1993; Kulkarni and Reddy, 1994). 
Recent studies have also demonstrated differences in microbial profiles for those with colorectal 
cancer, who were more likely to have higher levels of Bacteriodes/ Prevotella than normal 
controls (Sobhani et al., 2011). While the comprehensive stool analysis reports in this 
retrospective chart review did not contain data on these particular species, preliminary results 
showing increased likelihood of low levels of one beneficial bacterial species, Bifidobacter, 
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associated with markers of inflammation and impaired detoxification pathways suggest 
intriguing possibilities for prospective studies.   
The present study has several limitations. First, these data were collected as part of a 
retrospective chart review, from paper charts in an Integrative Medicine Clinic. During the 
abstraction process, it was noted that not all variables were available for all subjects. In addition, 
the comprehensive stool analysis reports were from two different laboratories, so many variables 
required recoding into normal/abnormal values based on the reference range of the particular lab, 
leading to loss of analytical information. Also, this population is distinct, being patients at the 
Integrative Medicine Clinic who, due to lack of reimbursement from insurance for physician 
visits, tend to be more affluent than patients from other specialties as they must pay many of the 
costs out-of-pocket.  These patients also tend to be sicker than other groups, having exhausted 
many other treatment options before arriving at the Integrative Medicine Clinic.  As a 
consequence, these results are not generalizable beyond this very specific group of patients, but 
do offer potential avenues for future research. 
 
  
 
 
 19 
BIBLIOGRAPHY 
Bäckhed F, Ding H, and Wang T. 2004. The gut microbiota as an environmental factor that 
regulates fat storage. Proceedings of the National Academy of Sciences 101(44):15718-23. 
 
Bottiglieri, T.  2002. S-adenosyl-L-methionine (SAMe): From the bench to the bedside – 
molecular basis of a pleiotropic molecule. Journal of Clinical Nutrition 76:1151-1157. 
 
Boutron-Ruault M-C, Marteau P, Lavergne-Slove A, Myara A, Gerhardt M-F, Franchisseur C, 
Bornet F, Eripolyp Study Group. 2005. Effects of a 3-mo consumption of short-chain 
fructo-oligosaccharides on parameters of colorectal carcinogenesis in patients with or 
without small or large colorectal adenomas. Nutrition and Cancer 53:160–168. 
Brady LJ, Gallaher DD, and Busta FF. 2000. The role of probiotic cultures in the prevention of 
colon cancer. The Journal of Nutrition 130:410S–414S. 
Castellarin M, Warren RL, Freeman JD, Dreolini L, Krzywinski M, Strauss J, Barnes R, Watson 
P, Allen-Vercoe E, Moore RA, et al. 2011. Fusobacterium nucleatum infection is prevalent 
in human colorectal carcinoma. Genome Research doi:10.1101/gr.126516.111. 
Corfe BM, Williams EA, Bury JP, Riley SA, Croucher LJ, Lai DY, and Evans CA. 2009. A 
study protocol to investigate the relationship between dietary fibre intake and fermentation, 
colon cell turnover, global protein acetylation and early carcinogenesis: the FACT study. 
BMC Cancer 9:332. 
Dai J, Liu W-Z, Zhao Y-P, Hu Y-B, and Ge Z-Z. 2007. Relationship between fecal lactoferrin 
and inflammatory bowel disease. Scandinavian Journal of Gastroenterology 42:1440–
1444. 
Delzenne N, Cherbut C, and Neyrinck A. 2003. Prebiotics: actual and potential effects in 
inflammatory and malignant colonic diseases. Current Opinion in Clinical Nutrition and 
Metabolic Care 6:581–586. 
Eckburg PB, Bik EM, Bernstein CN, Purdom E, Dethlefsen L, Sargent M, Gill SR, Nelson KE, 
and Relman DA. 2005. Diversity of the human intestinal microbial flora. Science 
308:1635–1638. 
Fanaro S, Chierici R, and Guerrini P. 2003. Intestinal microflora in early infancy: composition 
and development. Acta Paediatrica 91(441):48-55. 
 
Fotiadis CI, Stoidis CN, Spyropoulos BG, and Zografos ED. 2008. Role of probiotics, prebiotics 
and synbiotics in chemoprevention for colorectal cancer. World Journal of 
Gastroenterology 14:6453–6457. 
 
Frank DN, and Pace NR. 2001. Molecular-phylogenetic analyses of human gastrointestinal 
microbiota. Current Opinion in Gastroenterology 17:52–57. 
Frank DN, Zhu W, Sartor RB, and Li E. 2011. Investigating the biological and clinical 
 
 
20 
 
significance of human dysbioses. Trends in Microbiolology 19:427–434. 
Garrett WS, Gordon JI, and Glimcher LH. 2010. Homeostasis and inflammation in the intestine. 
Cell 140:859–870. 
Geier MS, Butler RN, and Howarth GS. 2006. Probiotics, prebiotics and synbiotics: a role in 
chemoprevention for colorectal cancer? Cancer Biology and Therapy 5:1265–1269. 
Hamer HM, Jonkers D, Venema K, Vanhoutvin S, Troost FJ, and Brummer RJ. 2008. Review 
article: the role of butyrate on colonic function. Alimentary Pharmacolology and Therapy 
27:104–119. 
Huycke MM, and Gaskins HR. 2004. Commensal bacteria, redox stress, and colorectal cancer: 
mechanisms and models. Experimental Biology and Medcine 229:586–597. 
Jernberg C, Löfmark S, Edlund C, and Jansson JK. 2010. Long-term impacts of antibiotic 
exposure on the human intestinal microbiota. Microbiology 156:3216–3223. 
Kelsall BL. 2008. Innate and adaptive mechanisms to control [corrected] pathological intestinal 
inflammation. Journal of Pathology 214:242–259. 
Kostic AD, Gevers D, Pedamallu CS, Michaud M, Duke F, Earl AM, Ojesina AI, Jung J, Bass 
AJ, Tabernero J, et al. 2011. Genomic analysis identifies association of Fusobacterium with 
colorectal carcinoma. Genome Research doi:10.1101/gr.126573.111. 
Kulkarni N, and Reddy BS. 1994. Inhibitory effect of Bifidobacterium longum cultures on the 
azoxymethane-induced aberrant crypt foci formation and fecal bacterial beta-
glucuronidase. Proceedings of the Society for Experimental Biology and Medicine 
207:278–283. 
Ley RE, Peterson DA, and Gordon JI. 2006. Ecological and evolutionary forces shaping 
microbial diversity in the human intestine. Cell 124:837–848. 
Lim CC, Ferguson LR, and Tannock GW. 2005. Dietary fibres as “prebiotics”: implications for 
colorectal cancer. Molecular Nutrition and Food Research 49:609–619. 
Liong MT. 2008. Roles of probiotics and prebiotics in colon cancer prevention: Postulated 
mechanisms and in-vivo evidence. International Journal of Molecular Science 9:854–863. 
Mackie RI, Sghir A, and Gaskins HR. 1999. Developmental microbial ecology of the neonatal 
gastrointestinal tract.  American Journal of Clinical Nutrition 69:1035S–1045S. 
Marchesi J, Dutilh B, Hall N, and Peters W. 2011. Towards the Human Colorectal Cancer 
Microbiome. PLoS One 6(5):e20447. 
 
McFarland L. 2008. Antibiotic-associated diarrhea: epidemiology, trends and treatment. Future 
Microbiology 3(5):563-78. 
 
 
 
 21 
Naito M, Frirdich E, Fields JA, Pryjma M, Li J, Cameron A, Gilbert M, Thompson SA, and 
Gaynor EC. 2010. Effects of sequential Campylobacter jejuni 81-176 lipooligosaccharide 
core truncations on biofilm formation, stress survival, and pathogenesis. Journal of 
Bacteriology 192:2182–2192. 
O'Keefe SJD. 2008. Nutrition and colonic health: the critical role of the microbiota. Current 
Opinion in Gastroenterology 24:51–58. 
Parry SD, Barton JR, and Welfare MR. 2005. Factors associated with the development of post-
infectious functional gastrointestinal diseases: does smoking play a role? European Journal 
of Gastroenterology and Hepatology  17:1071–1075. 
Pregliasco F, Anselmi G, Fonte L, Giussani F, Schieppati S, and Soletti L. 2008. A new chance 
of preventing winter diseases by the administration of synbiotic formulations. Journal of 
Clinical Gastroenterology 42 Suppl 3 Pt 2:S224–33. 
Rafter J, Bennett M, Caderni G, Clune Y, Hughes R, Karlsson, P. C., Klinder A, O'Riordan M, 
O'Sullivan GC, Pool-Zobel B, et al. 2007. Dietary synbiotics reduce cancer risk factors in 
polypectomized and colon cancer patients. American Journal of Clinical Nutrition 85:488–
496. 
Rafter JJ. 2002. Scientific basis of biomarkers and benefits of functional foods for reduction of 
disease risk: cancer. British Journal of Nutrition 88 Suppl 2:S219–24. 
Rowland IR. 2009. The role of the gastrointestinal microbiota in colorectal cancer. Current 
Pharmaceutical Design 15:1524–1527. 
Schwarz, G. 1978. Estimating the dimension of a model. Annals of Statistics 6: 461-464. 
Sobhani I, Tap J, Roudot-Thoraval F, Roperch JP, Letulle S, Langella P, Corthier G, Tran Van 
Nhieu J, and Furet JP. 2011. Microbial dysbiosis in colorectal cancer (CRC) patients. PLoS 
One 6:e16393. 
Strachan DP. 1989. Hay fever, hygiene, and household size. British Medical Journal 299:1259–
1260. 
Swidsinski A, Loening-Baucke V, Lochs H, and Hale L-P. 2005. Spatial organization of 
bacterial flora in normal and inflamed intestine: a fluorescence in situ hybridization study 
in mice. World Journal of Gastroenterology 11:1131–1140. 
Turnbaugh P, Ley R, Mahowald M, and Magrini V. 2006. An obesity-associated gut microbiome 
with increased capacity for energy harvest. Nature 444(7122):1027-31. 
 
Vella A, and Farrugia G. 1998. D-lactic acidosis: pathologic consequence of saprophytism. Mayo 
Clinic Proceedings 73:451–456. 
 
 
 
22 
 
Wang T, Cai G, Qiu Y, Fei N, Zhang M, Pang X, Jia W, Cai S, and Zhao L. 2011. Structural 
segregation of gut microbiota between colorectal cancer patients and healthy volunteers. 
Multidisciplinary Journal of Microbial Ecology doi:10.1038/ismej.2011.107. 
Wallace TC, Guarner F, Madsen K, Cabana MD, Gibson G, Hentges E, and Sanders ME. 2011. 
Human gut microbiota and its relationship to health and disease. Nutrition Reviews 69:392–
403. 
Weaver GA, Krause JA, Miller TL, and Wolin MJ. 1988. Short chain fatty acid distributions of 
enema samples from a sigmoidoscopy population: an association of high acetate and low 
butyrate ratios with adenomatous polyps and colon cancer. Gut 29:1539–1543. 
Worthley DL, Le Leu RK, Whitehall VL, Conlon M, Christophersen C, Belobrajdic D, Mallitt 
KA, Hu Y, Irahara N, Ogino S, et al. 2009. A human, double-blind, placebo-controlled, 
crossover trial of prebiotic, probiotic, and synbiotic supplementation: effects on luminal, 
inflammatory, epigenetic, and epithelial biomarkers of colorectal cancer. American Journal 
of Clinical Nutritionr 90:578–586. 
Zhang XB, and Ohta Y. 1993. Microorganisms in the gastrointestinal tract of the rat prevent 
absorption of the mutagen-carcinogen 3-amino-1,4-dimethyl-5H-pyrido(4,3-b)indole. 
Canadian Journal of Microbiology. 39:841–845. 
 
 
 
 
